Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness: A meta-analysis

Annals of Internal Medicine

Volumn 122, Issue 11, 1995, Pages 856-866

  Ioannidis, John P A ^a   Cappelleri, Joseph C ^a   Lau, Joseph ^a   Skolnik, Paul R ^a   Melville, Barbara ^a   Chalmers, Thomas C ^a   Sacks, Henry S ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; REVIEW; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0029057799     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-122-11-199506010-00009     Document Type: Review

References (35)

1. McLeod GX, Hammer SM. Zidovudine: five years later. Ann Intern Med. 1992;117:487-501.
2. Hirsch MS, D'Aquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med. 1993;328:1686-95.
3. Remick S, Follansbee S, Olson R, Pollard R, Reiter W, Salgo M. Safety and tolerance of zalcitabine (ddC, HIVID) in a double-blind, comparative trial (ACTG 114; N3300) [Abstract]. In: Program and Abstracts of the IXth International Conference on AIDS. Berlin, June 6-11 1993.
4. Sande MA, Carpenter CC, Cobbs CG, Holmes KK, Sanford JP. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti-Retroviral Therapy for Adult HIV-infected Patients. JAMA. 1993;270:2583-9.
5. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91.
6. Fischl MA, Richman DD, Causey DM, Grieco MH, Bryson Y, Mildvan D, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989;262:2405-10.
7. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990;322:941-9.
8. State-of-the-art conference on azidothymidine therapy for early HIV infection. Am J Med. 1990;89:335-44.
9. + cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 1993;329:297-303.
10. Hamilton JD, Hartigan PM, Simberkoff MS, Day PL, Diamond GR, Dickinson GM, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med. 1992;326:437-43.
11. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871-81.
12. Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schoeder B, Reitman D, et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials. 1981;2:31-49.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials. 1986;7:177-88.
14. Rothman KJ. Modern Epidemiology. Boston: Little, Brown; 1986.
15. SAS Institute, Inc. SAS Guide for Personal Computers. Version 6.03. Cary, North Carolina: SAS Institute; 1988.
16. Cooper DA, Pedersen C, Aiuti F, Vilde JL, Ruhnke M, Pehrson PO, et al. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group. AIDS. 1991;5:933-43.
17. Merigan TC, Amato DA, Balsley J, Power M, Price WA, Benoit S, et al. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic patients with hemophilia. NHF-ACTG 036 Study Group. Blood. 1991;78:900-6.
18. Fischl MA, Richman DD, Hansen N, Collier AC, Carey JT, Para MF, et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990;112:727-37.
19. Manucci PM, Gringeri A, Savidge G, Gatenby P, Laurian Y, Pabinger-Fasching I, et al. Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. Br J Haematol. 1994;86:174-7.
20. Mulder JW, Cooper DA, Mathiesen L, Sandstrom E, Clumeck N, Gatell JM, et al. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017). AIDS. 1994;8:313-21.
21. Cooper DA, Gatell JM. More on zidovudine in asymptomatic HIV infection [Letter]. N Engl J Med. 1994;330:1759.
22. Simberkoff MS, Hartigan PM, Hamilton JD, and the VA Cooperative Study Group. Long-term follow-up of VA trial comparing early versus late zidovudine for symptomatic HIV infection. In: Program and Abstracts of the VIIIth International Conference on AIDS; July 19-24, 1992. Abstract PoB 3723.
23. Phillips AN, Sabin CA. Zidovudine in asymptomatic HIV infection [Letter]. N Engl J Med. 1993;329:1895.
24. Lagakos S, Fischl MA, Stein DS, Lim L, Volberding P. Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA. 1991;266:2709-12.
25. Egger M, Neaton JD, Phillips AN, Smith GD. Concorde trial of immediate versus deferred zidovudine [Letter]. Lancet. 1994;343:1355.
26. Peto R, Collins R. Immediate versus deferred zidovudine [Letter]. Lancet. 1993;341:1022-3.
27. Richman DD, Fischl MA, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-7.
28. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group. N Engl J Med. 1994;330: 738-43.
29. Oddone EZ, Cowper P, Hamilton JD, Matchar DB, Hartigan P, Samsa G, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ. 1993;307:1322-5.
30. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993;37:1207-13.
31. Saab AJ, Hoover DR, He Y, Kingsley LA, Phair JP, and the Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr. 1994;7:287-95.
32. Lundgren JD, Phillips AN, Pedersen C, Clumeck N, Gatell JM, Johnson AM, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA. 1994;271:1088-92.
33. + lymphocytes. Proc Natl Acad Sci U S A. 1994;91:1104-8.
34. Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science. 1993;259:1749-54.
35. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH Jr, Reichman RC, et al for the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994;272:437-42.